Further investigation of this difference in the modulation of SESN2 expression by the Oxaliplatin and DHA combination is warranted, although the phenomenon may be associated with the unique genetic backgrounds of different cancer cell types and the variance in response to drugs. The gene discussed is SESN2; the disease is cancer.